Veliparib fails in two phase 3 trials.
Company nabs maintenance therapy use, but problems on breast cancer trial.
UK firm lays down the gauntlet in the PARP inhibitor battle.
UK pharma also gets $130m payment from Valeant.
Clovis’ Rubraca will compete against AstraZeneca rival.
Novocure’s Optune device shown to be safe and tolerable in recurrent ovarian cancer.
Oncology firm could make acquisition if ovarian cancer drug approved.